{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:46:10Z","timestamp":1759963570551,"version":"3.44.0"},"reference-count":35,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2015,12,8]]},"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We sought to establish the performance of cell-bound complement activation products (CB-CAPs) as a diagnostic tool to distinguish primary fibromyalgia (FM) from systemic lupus erythematosus (SLE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 75 SLE and 75 primary FM adult subjects who fulfilled appropriate classification criteria were enrolled prospectively. CB-CAPs (erythrocyte-C4d (EC4d) and B-lymphocyte-C4d (BC4d)) were determined by flow cytometry. Antinuclear antibodies (ANAs) were determined using indirect immunofluorescence while other autoantibodies were determined by solid-phase assays. The CB-CAPs in a multi-analyte assay with algorithm (MAAA) relied on two consecutive tiers of analysis that was reported as an overall positive or negative assessment. Test performance was assessed using sensitivity, specificity, positive and negative likelihood ratio (LR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>ANAs yielded 80% positives for SLE and 33% positives for FM. High CB-CAP expression (EC4d &gt;14\u2005units or BC4d &gt;60\u2005units) was 43% sensitive and 96% specific for SLE. The CB-CAPs in MAAA assessment was evaluable in 138 of the 150 subjects enrolled (92%) and yielded 60% sensitivity (CI 95% 48% to 72%) for SLE with no FM patient testing positive (100% specificity). A positive test result was associated with a strong positive LR for SLE (&gt;24, CI 95%; 6 to 102), while a negative test result was associated with a moderate negative LR (0.40; CI 95% 0.30 to 0.54).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our data indicate that CB-CAPs in MAAA can distinguish FM from SLE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2015-000127","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T22:15:25Z","timestamp":1454364925000},"page":"e000127","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products"],"prefix":"10.1136","volume":"3","author":[{"given":"Daniel J","family":"Wallace","sequence":"first","affiliation":[{"name":"Cedars Sinai Medical Center, Los Angeles, California, USA"},{"name":"Wallace Rheumatology Study Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart L","family":"Silverman","sequence":"additional","affiliation":[{"name":"Cedars Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Conklin","sequence":"additional","affiliation":[{"name":"Exagen Diagnostics, Vista, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derren","family":"Barken","sequence":"additional","affiliation":[{"name":"Exagen Diagnostics, Vista, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Dervieux","sequence":"additional","affiliation":[{"name":"Exagen Diagnostics, Vista, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"2025091512462029000_3.1.e000127.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071297"},{"key":"2025091512462029000_3.1.e000127.2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40258-014-0085-x","article-title":"Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes","volume":"12","author":"Oglesby","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"key":"2025091512462029000_3.1.e000127.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.20548"},{"key":"2025091512462029000_3.1.e000127.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.23177"},{"key":"2025091512462029000_3.1.e000127.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.38238"},{"key":"2025091512462029000_3.1.e000127.6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21896"},{"key":"2025091512462029000_3.1.e000127.7","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.22.2435"},{"key":"2025091512462029000_3.1.e000127.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.05.009"},{"key":"2025091512462029000_3.1.e000127.9","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282fb0268"},{"key":"2025091512462029000_3.1.e000127.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"2025091512462029000_3.1.e000127.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.34380"},{"key":"2025091512462029000_3.1.e000127.12","first-page":"368","article-title":"A prospective evaluation of 118 patients with the fibromyalgia syndrome: prevalence of Raynaud's phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction","volume":"13","author":"Dinerman","year":"1986","journal-title":"J Rheumatol"},{"key":"2025091512462029000_3.1.e000127.13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/art.1780381014","article-title":"Identification of patient subsets among those presumptively diagnosed with, referred, and\/or followed up for systemic lupus erythematosus at a large tertiary care center","volume":"38","author":"Calvo-Al\u00e9n","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2025091512462029000_3.1.e000127.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-8062.2009.00135.x"},{"key":"2025091512462029000_3.1.e000127.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.34669"},{"key":"2025091512462029000_3.1.e000127.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep161"},{"key":"2025091512462029000_3.1.e000127.17","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-004-0046-8"},{"key":"2025091512462029000_3.1.e000127.18","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000056"},{"key":"2025091512462029000_3.1.e000127.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"2025091512462029000_3.1.e000127.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"2025091512462029000_3.1.e000127.21","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/acr.22349","article-title":"Development and validation of the Lupus Impact Tracker: a patient-completed tool for clinical practice to assess and monitor the impact of systemic lupus erythematosus","volume":"66","author":"Jolly","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025091512462029000_3.1.e000127.22","doi-asserted-by":"publisher","DOI":"10.1186\/ar2783"},{"key":"2025091512462029000_3.1.e000127.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135"},{"key":"2025091512462029000_3.1.e000127.24","doi-asserted-by":"crossref","first-page":"149316","DOI":"10.1155\/2014\/149316","article-title":"Interpretation of ANA indirect immunofluorescence test outside the darkroom using NOVA view compared to manual microscopy","volume":"2014","author":"Copple","year":"2014","journal-title":"J Immunol Res"},{"key":"2025091512462029000_3.1.e000127.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.01.013"},{"key":"2025091512462029000_3.1.e000127.26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2002.10750.x"},{"key":"2025091512462029000_3.1.e000127.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66422-7"},{"key":"2025091512462029000_3.1.e000127.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03330370053031"},{"key":"2025091512462029000_3.1.e000127.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7005.619"},{"key":"2025091512462029000_3.1.e000127.30","doi-asserted-by":"publisher","DOI":"10.1214\/ss\/1009213286"},{"key":"2025091512462029000_3.1.e000127.31","doi-asserted-by":"publisher","DOI":"10.2307\/2685469"},{"key":"2025091512462029000_3.1.e000127.32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3949\/ccjm.69.2.143","article-title":"Tired, aching, ANA-positive: does your patient have lupus or fibromyalgia?","volume":"69","author":"Blumenthal","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"2025091512462029000_3.1.e000127.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.24699"},{"key":"2025091512462029000_3.1.e000127.34","unstructured":"Giles I , Isenberg D . Antinuclear antibodies: An overview. In: Wallace DJ , Hahn BH, eds . Dubois\u2019 Lupus Erythematosus. 7th edn. Lippincott Williams & Wilkins, 2007:432\u201341."},{"key":"2025091512462029000_3.1.e000127.35","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.84"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2015-000127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T19:46:30Z","timestamp":1757965590000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2015-000127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,2,1]]},"published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1136\/lupus-2015-000127"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2015-000127","relation":{},"ISSN":["2053-8790"],"issn-type":[{"type":"electronic","value":"2053-8790"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}